Imatinib in Patients With Desmoid Tumor and Chondrosarcoma

Exclusion Criteria

• •Previous treatment with any other investigational or not investigational agents within 28 days of first day of study drug dosing
• •Other primary malignancy with \<5 years clinically assessed disease-free interval, except basal cell skin cancer or cervical carcinoma in situ.
• •Grade III/IV cardiac problems as defined by the New York Heart Association Criteria
• •Severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, or active uncontrolled infection)
• •Known brain metastasis.
• •Known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis).
• •Known diagnosis of human immunodeficiency virus (HIV) infection.
• •Previous radiotherapy to \>/=25% of the bone marrow or within the previous 2 months on target lesion.
• •Major surgery within 2 weeks prior to study entry.
• •Expected non-compliance to medical regimens (e.g. psychiatric diseases).